Excellent DD. That guy heads the "Illinois Sports Medicine, Orthopedics, and Stem Cell Center" in the Chicago area, near Northwestern University. His practice is "limited to the non-surgical treatment of orthopedic disorders, including world-leading stem cell and platelet rich plasma treatment for arthritis and sports injuries." With that many shares, he joins the other insiders who have plenty of motivation to want to relist.... or, as you point out, to be bought. Of course, being bought out is the ultimate panacea for beaten down shareholders like us! :)